Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Non-Current Liabilities: 2021-2024

Historic Total Non-Current Liabilities for Relay Therapeutics (RLAY) over the last 3 years, with Mar 2024 value amounting to $84.3 million.

  • Relay Therapeutics' Total Non-Current Liabilities fell 31.33% to $84.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $84.3 million, marking a year-over-year decrease of 31.33%. This contributed to the annual value of $78.8 million for FY2023, which is 32.77% down from last year.
  • Per Relay Therapeutics' latest filing, its Total Non-Current Liabilities stood at $84.3 million for Q1 2024, which was up 7.02% from $78.8 million recorded in Q4 2023.
  • Relay Therapeutics' Total Non-Current Liabilities' 5-year high stood at $126.0 million during Q3 2022, with a 5-year trough of $47.4 million in Q2 2021.
  • Over the past 3 years, Relay Therapeutics' median Total Non-Current Liabilities value was $100.6 million (recorded in 2023), while the average stood at $97.6 million.
  • In the last 5 years, Relay Therapeutics' Total Non-Current Liabilities spiked by 151.74% in 2022 and then tumbled by 32.77% in 2023.
  • Relay Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $60.4 million in 2021, then spiked by 94.07% to $117.2 million in 2022, then plummeted by 32.77% to $78.8 million in 2023, then crashed by 31.33% to $84.3 million in 2024.
  • Its Total Non-Current Liabilities was $84.3 million in Q1 2024, compared to $78.8 million in Q4 2023 and $100.6 million in Q3 2023.